Vaccines as treatment for melanoma: an update review
-
By
-
Jinjue Zhang
-
Qing Cao
-
Ying Cen
-
Ling Zhang
-
Junjie Chen
-
June 9, 2026
-
Clinical Scorecard: Therapeutic Vaccines for Melanoma: A Comprehensive Review of Recent Advances
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Therapeutic vaccines aim to prime the immune system to combat melanoma by inducing T-cell responses. |
| Target Population | |
| Care Setting | |
Key Highlights
- Talimogene laherparevec (T-VEC) is the only FDA-approved vaccine for melanoma.
- Sixteen distinct vaccine methodologies have been evaluated in phase III clinical trials.
- Most vaccine strategies show acceptable safety profiles but limited clinical efficacy.
Guideline-Based Recommendations
Diagnosis
- Clinical trials must include melanoma patients and describe their outcomes.
Management
Monitoring & Follow-up
- Monitor immune responses and clinical outcomes in patients receiving therapeutic vaccines.
Risks
- Limited clinical efficacy and potential adverse effects associated with vaccine therapies.
Patient & Prescribing Data
Patients with advanced melanoma or recurrent disease.
Immunotherapy has shown great efficacy, but a significant proportion of patients do not respond.
Clinical Best Practices
Related Resources & Content
